A research team has demonstrated that the replacement of microglia is possible – bringing personalised cell therapies for brain diseases a step forward.
Microglia are essential for healthy brain function. Defective microglia are increasingly linked to the development of neurodegenerative disorders.
“Microglia are unique,” said researcher Professor Kiavash Movahedi. “They originate early in embryonic development and maintain themselves throughout life without being replaced by new cells from the blood. That makes them special, but also vulnerable.”
Until now, replacing faulty microglia has posed a major challenge. The researchers have now shown that this is indeed possible. By applying specific strategies, certain white blood cells, so-called monocytes, can cross the blood-brain barrier and settle in the brain as new microglia.
“This opens up new avenues for future therapies,” says Movahedi.
However, the monocytes do not fully adopt the identity of the original microglia. “Although they mimic microglia functions, they remain molecularly distinct,” says Jonathan Bastos, PhD researcher on the project and first author of the article.
“This may be a disadvantage, as the new cells may not be able to fully replicate the normal functions of microglia.”
A key discovery is that the origin of the cells is crucial. Only monocytes derived from embryonic precursors can develop into true microglia. This insight paves the way for new cell therapies: by using embryonic cells or stem cell-derived, microglia-like cells, patients may one day be effectively treated.
The research team is now continuing this work, aiming to develop strategies for personalised cell therapy, using patients’ own cells to replace defective microglia. Additionally, the researchers envision improving these new microglia so they can, for example, produce therapeutic substances directly within the brain to actively combat disease.
The study was conducted in collaboration with international partners and was supported by a simultaneous publication by American colleagues, who demonstrated that the new replacement therapy can actually improve brain conditions in a mouse model.
Movahedi said: “The work of colleague F. Chris Bennett provides evidence that this new approach truly holds potential.
“The impact of neurodegenerative diseases is growing rapidly, and effective therapies are urgently needed. Our results lay a foundation on which to build innovative treatments that not only alleviate symptoms but actually tackle the root causes.
